A systematic review and meta-analysis suggests that preconception exposure to certain antibiotic classes increases the risk of infertility, miscarriage, and congenital anomalies, researchers reported last week in eClinicalMedicine.
While the risks of antibiotic use during pregnancy have been well documented, less attention has been paid to the potential of antibiotic use during preconception—the months before pregnancy when women can take steps to improve their health and the health of their future child. To summarize the existing evidence, researchers with the Chinese University of Hong Kong identified 15 articles on preconception antibiotic exposure that were published from 1975 to 2023 and involved more than 1.2 million women. The primary outcomes of interest included infertility, pregnancy rate, fecundability rate, miscarriage, and congenital malformation, which were measured by odds ratios (OR), relative risks (RR), and fecundability ratios (FR).
Significant increases in risk of infertility, miscarriage, congenital malformations
The meta-analysis found that macrolide exposure in the pre-conception period was associated with a 35% delay in the probability of getting pregnant (FR, 0.65; 95% confidence interval [CI], 0.48 to 0.88). Sulfonamide users were 2.35 times more likely to develop infertility (OR, 2.35; 95% CI, 1.86 to 2.97). Preconception exposure to all antibiotic classes was associated with 34% increased risk of spontaneous miscarriage (RR, 1.34; 95% CI, 1.16 to 1.53), while trimethoprim intake increased the odds of congenital malformations by 85% (OR, 1.85; 95% CI, 1.54 to 2.23).
In contrast, use of beta-lactams other than penicillin G reduced the odds of infertility by 64% (OR, 0.36; 95% CI, 0.26 to 0.50) and use of quinolones reduced the risk by 13% (OR, 0.87; 95% CI, 0.77 to 0.99).
"Our findings appeal to the critical need for careful consideration of antibiotic use in women of reproductive age to safeguard reproductive health and mitigate potential adverse events in pregnancy," the study authors wrote.
The authors say more studies are needed to uncover the mechanisms of how preconception antibiotics influence reproductive health and to explore novel therapeutic strategies, such as probiotics, that could enhance female health.